WESTMINSTER, Colo.--(BUSINESS WIRE)--Apr. 15, 2009--
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the Company
will present data from an in vitro study examining the potency of
pralatrexate in colon, breast, ovarian, lung, prostate, and head and
neck cancer cell lines at the upcoming American Association for Cancer
Research 100th Annual Meeting to be held in Denver, CO on April 18 - 22.
|
Presentation details are as follows:
|
|
|
|
Date/Time: Sunday, April 19, 2009, 1- 5 p.m. (Mountain)
|
|
Session: Experimental and Molecular Therapeutics 5
|
|
Poster Title: Cytotoxicity of Pralatrexate, a Novel Synthetic
Antifolate, in Human Cancer Cell Lines
|
|
Abstract Number: 1686
|
|
Location: Hall B-F, Poster Section 33, Poster Number 6
|
About Pralatrexate
Pralatrexate is a novel targeted antifolate designed to accumulate
preferentially in cancer cells. Based on preclinical studies, the
Company believes that pralatrexate selectively enters cells expressing
RFC-1, a protein that is over expressed on cancer cells compared to
normal cells. Once inside cancer cells, pralatrexate is efficiently
polyglutamylated, which leads to high intracellular drug retention.
Polyglutamylated pralatrexate essentially becomes “trapped” inside
cancer cells, making it less susceptible to efflux-based drug
resistance. Acting on the folate pathway, pralatrexate interferes with
DNA synthesis and triggers cancer cell death. The Company believes
pralatrexate has the potential to be delivered as a single agent or in
combination therapy regimens.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the treatment of
cancer. The Company’s lead product candidate, pralatrexate, is a novel
targeted antifolate designed to accumulate preferentially in cancer
cells. In February 2009, the Company announced the final results from
PROPEL, the Company’s pivotal Phase 2 (PROPEL) trial of pralatrexate in
patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
The PROPEL trial was conducted under an agreement reached with the U.S.
Food and Drug Administration under its special protocol assessment (SPA)
process. Based on the results of the PROPEL trial, the Company submitted
a New Drug Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in March
2009. The Company is also investigating pralatrexate in patients with
non-small cell lung cancer, bladder cancer and a range of lymphoma
sub-types. The Company currently retains exclusive worldwide rights to
pralatrexate for all indications. For additional information, please
visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that may
cause actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31,
2008 and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof, and
the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the
date of this presentation, except as required by law.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 303-426-6262
mgreer@allos.com
